-transparent.png){kind=logo}
Ifosfamide was tested in a phase II study in 12 evaluable patients with advanced malignant melanoma. The drug was administered at the dose of 3 g/m2 on days one and two every 3-weeks. Seven patients were not previously treated and 5 received only minimal prior chemotherapy. Visceral involvement was present in 9 patients, and the remaining 3 had only soft tissue lesions. No patient showed objective tumor response. Mild vomiting was observed in 75% of patients; alopecia occurred in all of them. No other major side effects were observed, in particular, myelotoxicity and urotoxicity. Lack of response advised us to discontinue patient accrual. Our data do not support a therapeutic role of ifosfamide at the given dose schedule in the treatment of metastatic malignant melanoma.
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
January 1990,
Annals of oncology : official journal of the European Society for Medical Oncology,
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
January 1980,
Journal of cancer research and clinical oncology,
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
January 1984,
Investigational new drugs,
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
December 1987,
Cancer treatment reports,
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
June 1985,
Cancer treatment reports,
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
April 1999,
Lung cancer (Amsterdam, Netherlands),
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
December 1982,
Seminars in oncology,
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
March 2009,
European journal of cancer (Oxford, England : 1990),
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
January 1991,
Cancer chemotherapy and pharmacology,
E Negretti, and
L Ferrari, and
V Bonfante, and
E Bajetta
January 1979,
Cancer treatment reports,
